Autus Valve Early Feasibility Study
Autus størrelsesjusterbar ventil for kirurgisk lungeventilerstatning tidlig mulighetsstudie
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Ann and Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan - Mott Children's Hospital
-
-
New York
-
New York, New York, Forente stater, 10032
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27703
- Duke University
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Children's Hospital of Philadelphia
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- University of Utah - Intermountain Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Seattle Children's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.
-
Age 18 months to 16 years.
-
Male or female.
-
Subject has a native or repaired right ventricular outflow tract.
-
Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).
-
Subject has at least one of the following echocardiographic findings:
- Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
- Moderate or greater pulmonary regurgitation;
- Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
-
Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).
-
Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.
-
Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are met:
- Subject requires valve replacement in a non-pulmonary position.
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
- Subject has pulmonary atresia and major aortopulmonary collaterals.
- Subject has significant peripheral pulmonary artery stenosis.
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
- Subject has active endocarditis or a history of infective endocarditis.
- Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
- Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
- Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
- Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
- Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
- Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
- Subject needs emergency cardiac or vascular surgery or intervention.
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
- Subject or parent/legal representative refuses blood transfusions.
- Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
- Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Autus Valve Arm
Pulmonary Valve Replacement Surgery with the Autus Valve |
Pulmonary valve replacement surgery with the Autus Valve |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Valve Implantation Primary Safety Endpoint
Tidsramme: 30 Days post-valve implantation
|
Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:
|
30 Days post-valve implantation
|
|
Valve Implantation Primary Effectiveness Endpoint
Tidsramme: 6 Months post-valve implantation
|
Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:
|
6 Months post-valve implantation
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Other Safety Outcome - Composite
Tidsramme: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:
|
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Mortality
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Mortality, including: all cause, cardiac-related, procedure-related and device-related |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve Thrombosis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Valve thrombosis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Thromboembolism
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Thromboembolism |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Cardiac or Valve Intervention
Tidsramme: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Other cardiac or valve intervention (surgical or transcatheter) |
30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Major Hemorrhage
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Major hemorrhage |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Endocarditis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Endocarditis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Hemolysis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Hemolysis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Device Explantation
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Device explantation |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Adverse Events (AE)
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Adverse events |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve/Stent Fracture
Tidsramme: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure. |
pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Tidsramme: Immediately Post-Valve Implant Procedure
|
To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):
|
Immediately Post-Valve Implant Procedure
|
|
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Right Ventricular Measures
Tidsramme: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Left Ventricular Measures
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Modified Ross Functional Classification
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Modified Ross Functional Class as assessed by the Site Investigators |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - PedsQL - Cardiac Module
Tidsramme: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel. |
Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
|
Other Post-Implant Valve Expansion Safety Outcome - Composite
Tidsramme: 30 days after each post-implant valve expansion procedure
|
Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:
|
30 days after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Tidsramme: Immediately after each post-implant valve expansion procedure
|
To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:
|
Immediately after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Tidsramme: 6 months after each post-implant valve expansion procedure
|
Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:
|
6 months after each post-implant valve expansion procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- AUT-CP-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .